Radioiodine for remnant ablation and therapy of metastatic disease

摘要: Radioiodine is considered an effective and low-risk therapy modality of advanced differentiated thyroid cancer. For patients without lymph-node or distant metastases low stages the primary tumor, debate ongoing about necessity remnant tissue ablation in adjuvant setting. On basis evidence from retrospective studies, until results controlled prospective randomized trials become available, (131)I with tumors >1 cm advisable. ablation, individual dosimetry not obligatory. By contrast, effectiveness locally and/or metastatic disease can be improved by dosimetry. practical reasons, approach delivering maximal possible radiation dose to tumor exceeding a critical blood approximately 2 Gy seems advantageous. The availability recombinant human TSH (rhTSH) has quality life reduces exposure healthy nonthyroid compared stimulation through levothyroxine withdrawal. In metastases, rhTSH only off-label use, which especially elderly frail may benefit, as they most severely suffer hypothyroidism caused hormone